‘Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028' report delivers an in - depth understanding of the disease, historical & forecasted epidemiology of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
Geography Covered
Advanced Renal Cell Carcinoma Epidemiology
According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. It is more common in males than in females (ratio of 2 - 3:1) and in persons with a history of smoking.
Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. They usually occur in 50 - 70 year old patients and macroscopic hematuria occurs in 60% of the cases.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Advanced Renal Cell Carcinoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 - 2028 for the following aspects:
Report Scope
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
- China
Advanced Renal Cell Carcinoma Epidemiology
According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. It is more common in males than in females (ratio of 2 - 3:1) and in persons with a history of smoking.
Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. They usually occur in 50 - 70 year old patients and macroscopic hematuria occurs in 60% of the cases.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Advanced Renal Cell Carcinoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 - 2028 for the following aspects:
- Diagnosed Incident Cases of Renal Cell Carcinoma (RCC)
- Gender - specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
- Subtype - specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
- Stage - specific Diagnosed Incident Cases of RCC
- Total Cases of Advanced/Metastatic RCC
Report Scope
- The report covers the detailed overview of Advanced Renal Cell Carcinoma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
- The report provides insight about the historical and forecasted patient pool for G8 countries covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
- The report assesses the disease risk and burden and highlights the unmet needs of Advanced Renal Cell Carcinoma.
- The report helps to recognize the growth opportunities in the G8 countries with respect to the patient population.
- The report provides the segmentation of the disease epidemiology by type - specific cases and severity specific cases of Advanced Renal Cell Carcinoma in the G8 countries.
- 10 - Year Forecast of Advanced Renal Cell Carcinoma epidemiology
- G8 countries Coverage
- Total Incident Cases of Advanced Renal Cell Carcinoma
- Incident Cases according to segmentation
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
1. Key Insights
2. Disease Background and Overview: Advanced Renal Cell carcinoma
2.1. Introduction
2.2. Histologic Subtypes and Related Molecular Pathways
2.2.1. Clear Cell Renal Cell Carcinoma
2.2.2. Non-clear-cell renal cell carcinomas
2.3. Biology and pathology of renal cell carcinoma
2.4. Pathophysiology
2.5. Risk Factors of Advanced Renal Cell Carcinoma
2.6. Mechanisms of Renal Cell Carcinoma
2.6.1. Genes and pathways
2.6.2. Tumor heterogeneity and cancer evolution
2.6.3. Immune infiltration and the tumor microenvironment
2.7. Staging of renal cell carcinoma
2.7.1. TNM Staging
2.7.2. Composite grading systems for renal carcinoma
2.7.3. Fuhrman Nuclear Grade
2.8. Genetic Pathology of renal cell carcinoma
2.8.1. Von Hippel-Lindau gene
2.8.2. Protein polybromo-1 gene
2.8.3. BRCA1-associated protein-1
2.8.4. The mTOR pathway
2.9. Epigenetics of RCC
2.10. Tumor Behavior and Prognostic Molecular Markers
2.11. Metabolic pathways and targets in renal cell carcinoma
2.11.1. The Glutaminase Pathway
2.11.2. Other metabolic pathways and targets
2.12. Role of the Immune System in Renal Cell Carcinoma
2.12.1. The programmed death-1 receptor (PD-1 receptor) pathway
2.12.2. Interaction between Angiogenesis and the Anti-Tumor Immune Response
2.13. Biomarkers
2.13.1. Molecular biomarkers
2.13.2. Inflammatory Proteins
2.13.3. Molecular Markers in Urine
2.14. Diagnosis
2.14.1. Size, Extent of Invasion Outside of the Kidney
2.14.2. Genomic implications
2.14.3. Histopathological confirmation
2.14.4. Radiologic Evaluation
2.14.5. Screening and Imaging
2.14.6. Preoperative Evaluation
2.15. Diagnostic Guidelines
2.15.1. European Association of Urology Guidelines on Renal Cell Carcinoma: 2019
2.15.2. Renal Mass and Localized Renal Cancer: AUA Guideline (2017)
2.15.3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis
2.16. Nutshell: Advanced Renal Cell Carcinoma
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. G8 Countries Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC)
4. Country Wise-Epidemiology of Advanced Renal Cell Carcinoma (RCC)
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States
4.1.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States
4.1.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States
4.1.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States
4.1.6. Advanced/Metastatic RCC Total Cases in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany
4.3.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany
4.3.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany
4.3.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany
4.3.5. Advanced/Metastatic RCC Total Cases in Germany
4.4. France
4.4.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France
4.4.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France
4.4.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France
4.4.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France
4.4.5. Advanced/Metastatic RCC Total Cases in France
4.5. Italy
4.5.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy
4.5.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy
4.5.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy
4.5.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy
4.5.5. Advanced/Metastatic RCC Total Cases in Italy
4.6. Spain
4.6.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain
4.6.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain
4.6.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain
4.6.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain
4.6.5. Advanced/Metastatic RCC Total Cases in Spain
4.7. United Kingdom
4.7.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom
4.7.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom
4.7.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom
4.7.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom
4.7.5. Advanced/Metastatic RCC Total Cases in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan
4.8.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan
4.8.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan
4.8.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan
4.8.6. Advanced/Metastatic RCC Total Cases in Japan
4.9. China
4.9.1. Assumptions and Rationale
4.9.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China
4.9.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China
4.9.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China
4.9.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China
4.9.6. Advanced/Metastatic RCC Total Cases in China
5. Appendix
5.1. Report Methodology
6. Publisher Capabilities
7. Disclaimer
8. About the Publisher
2. Disease Background and Overview: Advanced Renal Cell carcinoma
2.1. Introduction
2.2. Histologic Subtypes and Related Molecular Pathways
2.2.1. Clear Cell Renal Cell Carcinoma
2.2.2. Non-clear-cell renal cell carcinomas
2.3. Biology and pathology of renal cell carcinoma
2.4. Pathophysiology
2.5. Risk Factors of Advanced Renal Cell Carcinoma
2.6. Mechanisms of Renal Cell Carcinoma
2.6.1. Genes and pathways
2.6.2. Tumor heterogeneity and cancer evolution
2.6.3. Immune infiltration and the tumor microenvironment
2.7. Staging of renal cell carcinoma
2.7.1. TNM Staging
2.7.2. Composite grading systems for renal carcinoma
2.7.3. Fuhrman Nuclear Grade
2.8. Genetic Pathology of renal cell carcinoma
2.8.1. Von Hippel-Lindau gene
2.8.2. Protein polybromo-1 gene
2.8.3. BRCA1-associated protein-1
2.8.4. The mTOR pathway
2.9. Epigenetics of RCC
2.10. Tumor Behavior and Prognostic Molecular Markers
2.11. Metabolic pathways and targets in renal cell carcinoma
2.11.1. The Glutaminase Pathway
2.11.2. Other metabolic pathways and targets
2.12. Role of the Immune System in Renal Cell Carcinoma
2.12.1. The programmed death-1 receptor (PD-1 receptor) pathway
2.12.2. Interaction between Angiogenesis and the Anti-Tumor Immune Response
2.13. Biomarkers
2.13.1. Molecular biomarkers
2.13.2. Inflammatory Proteins
2.13.3. Molecular Markers in Urine
2.14. Diagnosis
2.14.1. Size, Extent of Invasion Outside of the Kidney
2.14.2. Genomic implications
2.14.3. Histopathological confirmation
2.14.4. Radiologic Evaluation
2.14.5. Screening and Imaging
2.14.6. Preoperative Evaluation
2.15. Diagnostic Guidelines
2.15.1. European Association of Urology Guidelines on Renal Cell Carcinoma: 2019
2.15.2. Renal Mass and Localized Renal Cancer: AUA Guideline (2017)
2.15.3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis
2.16. Nutshell: Advanced Renal Cell Carcinoma
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. G8 Countries Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC)
4. Country Wise-Epidemiology of Advanced Renal Cell Carcinoma (RCC)
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States
4.1.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States
4.1.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States
4.1.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States
4.1.6. Advanced/Metastatic RCC Total Cases in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany
4.3.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany
4.3.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany
4.3.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany
4.3.5. Advanced/Metastatic RCC Total Cases in Germany
4.4. France
4.4.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France
4.4.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France
4.4.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France
4.4.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France
4.4.5. Advanced/Metastatic RCC Total Cases in France
4.5. Italy
4.5.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy
4.5.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy
4.5.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy
4.5.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy
4.5.5. Advanced/Metastatic RCC Total Cases in Italy
4.6. Spain
4.6.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain
4.6.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain
4.6.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain
4.6.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain
4.6.5. Advanced/Metastatic RCC Total Cases in Spain
4.7. United Kingdom
4.7.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom
4.7.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom
4.7.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom
4.7.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom
4.7.5. Advanced/Metastatic RCC Total Cases in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan
4.8.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan
4.8.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan
4.8.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan
4.8.6. Advanced/Metastatic RCC Total Cases in Japan
4.9. China
4.9.1. Assumptions and Rationale
4.9.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China
4.9.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China
4.9.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China
4.9.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China
4.9.6. Advanced/Metastatic RCC Total Cases in China
5. Appendix
5.1. Report Methodology
6. Publisher Capabilities
7. Disclaimer
8. About the Publisher
Note: Product cover images may vary from those shown
![RCC [2017]: Bulletin #2 - Product Image](http://www.researchandmarkets.com/product_images/7668/7668718_60px_jpg/rcc_[2017]_bulletin_2.jpg)